Clinical Approach to Medical Management of Type 2 Diabetes

More documents

Recommendations

Info

Relative risk reduction for metformin treatment (%) UKPDS 34: relative risk reduction with metformin vs conventional treatment 0 10 20 30 40 50 -32 ** -42 * -36 * -39 -41 * * p < 0.05 ** p < 0.01 N=1704 patients Lancet 1998;352:854–65
10-Year Follow-up of Intensive control in Type 2 DM Hazard Ratios for Prespecified Clinical Outcomes Holman R et al. N Engl J Med 2008
Page 1 and 2: Clinical Approach to Medical Manage
Page 3 and 4: Outline: 1. Glycemic Targets in Typ
Page 5 and 6: Glycemic Goals of Therapy in Outpat
Page 7 and 8: Adjusted Hazard Ratio for Clinical
Page 9 and 10: Benefit assessment of long-term blo
Page 11 and 12: Outline: 1. Glycemic Targets in Typ
Page 13 and 14: Type 2 DM Treatment - Practical Tip
Page 15: The Biguanides: Basic Characteristi
Page 19 and 20: Metformin: Old Drug, New Targets Li
Page 21 and 22: Secretagogues: Sulfonylureas and th
Page 23 and 24: Secretagogues: Sulfonylureas and th
Page 25 and 26: Sulfonylurea Versus Newer Agents: G
Page 27 and 28: Basic Characteristics of Glitazones
Page 29 and 30: Pioglitazone • Is not associated
Page 31 and 32: The α-Glucosidase Inhibitors: Basi
Page 33 and 34: Types of Insulins • Basal insulin
Page 35 and 36: Prandial Versus Basal Insulin: The
Page 37 and 38: Insulin Initiation and Titration
Page 39 and 40: Colesevelam vs. Placebo in combinat
Page 41 and 42: Cycloset Safety Trial HR Bromocript
Page 43 and 44: • N=656 • DM2 for ~12 yrs • B
Page 45 and 46: So, we have 11 different classes of
Page 47 and 48: Comparative Effectiveness and Safet
Page 49 and 50: Pooled between-group differences in
Page 51 and 52: Effect of Antihyperglycemic Agents
Page 53 and 54: Yearly Cost for Different Antihyper
Page 55 and 56: 2012 Position Statement of the ADA
Page 57: Thank You !

Clinical Approach to Medical Management of Type 2 Diabetes

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?